| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1097/PPO.0B013E31803C72BA |
| P698 | PubMed publication ID | 17464243 |
| P2093 | author name string | Janice M Mehnert | |
| Wm Kevin Kelly | |||
| P2860 | cites work | Crystal structure of the nucleosome core particle at 2.8 A resolution | Q22122355 |
| P433 | issue | 1 | |
| P304 | page(s) | 23-29 | |
| P577 | publication date | 2007-01-01 | |
| P1433 | published in | The Cancer Journal | Q2589130 |
| P1476 | title | Histone deacetylase inhibitors: biology and mechanism of action | |
| P478 | volume | 13 |
| Q30445663 | A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study |
| Q36528653 | A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium study |
| Q42466733 | Acute alcohol exposure induces apoptosis and increases histone H3K9/18 acetylation in the mid-gestation mouse lung |
| Q47610009 | Antiproliferative effects of TSA, PXD‑101 and MS‑275 in A2780 and MCF7 cells: Acetylated histone H4 and acetylated tubulin as markers for HDACi potency and selectivity |
| Q34384713 | Butyrate, an HDAC inhibitor, stimulates interplay between different posttranslational modifications of histone H3 and differently alters G1-specific cell cycle proteins in vascular smooth muscle cells |
| Q37715009 | Chapter 11 - Solid lipid nanoparticles for brain tumors therapy: State of the art and novel challenges |
| Q37234005 | Chemical and pathway proteomics: powerful tools for oncology drug discovery and personalized health care. |
| Q33564416 | Chemical modifier screen identifies HDAC inhibitors as suppressors of PKD models |
| Q36937117 | Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis. |
| Q37096490 | Cholesterylbutyrate solid lipid nanoparticles as a butyric acid prodrug. |
| Q36537920 | Combination therapy: histone deacetylase inhibitors and platinum-based chemotherapeutics for cancer |
| Q35779296 | Compensatory functions of histone deacetylase 1 (HDAC1) and HDAC2 regulate transcription and apoptosis during mouse oocyte development |
| Q40039538 | Competitive inhibition of histone deacetylase activity by trichostatin A and butyrate |
| Q38056842 | Deregulated chromatin remodeling in the pathobiology of brain tumors |
| Q34822075 | Determination of chidamide in rat plasma by LC-MS and its application to pharmacokinetics study |
| Q33808504 | Enhancement of vaccinia virus based oncolysis with histone deacetylase inhibitors |
| Q33802356 | Epigenetic Targeting of Transforming Growth Factor β Receptor II and Implications for Cancer Therapy |
| Q37287032 | Epigenetic changes in gliomas |
| Q95853354 | Histone Deacetylase Inhibitors: A Prospect in Drug Discovery |
| Q35213401 | Histone deacetylase (HDAC) activity is critical for embryonic kidney gene expression, growth, and differentiation. |
| Q36777934 | Histone deacetylase 1 (HDAC1) regulates histone acetylation, development, and gene expression in preimplantation mouse embryos |
| Q36814349 | Histone deacetylase inhibition: an important mechanism in the treatment of lymphoma |
| Q43153290 | Histone deacetylase inhibitors attenuate acute lung injury during cecal ligation and puncture-induced polymicrobial sepsis. |
| Q33380457 | Histone deacetylase inhibitors: a new mode for inhibition of cholesterol metabolism |
| Q37962335 | Interplay between histone deacetylases and autophagy--from cancer therapy to neurodegeneration |
| Q46781524 | Interpretation of plasma amino acids in the follow-up of patients: the impact of compartmentation |
| Q42098631 | Novel inhibitor of Plasmodium histone deacetylase that cures P. berghei-infected mice |
| Q37492540 | Pharmacologic and chemical adjuvants in tumor virotherapy |
| Q36408642 | Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors |
| Q33590788 | Pretreatment with anti-oxidants sensitizes oxidatively stressed human cancer cells to growth inhibitory effect of suberoylanilide hydroxamic acid (SAHA). |
| Q35822297 | Receptor-Independent Ectopic Activity of Prolactin Predicts Aggressive Lung Tumors and Indicates HDACi-Based Therapeutic Strategies |
| Q91655095 | Regulation of colonic epithelial butyrate transport: Focus on colorectal cancer |
| Q39914674 | Results of a phase II study of vorinostat in combination with intravenous fludarabine, mitoxantrone, and dexamethasone in patients with relapsed or refractory mantle cell lymphoma: an interim analysis |
| Q39042777 | SIRT1 is upregulated in cutaneous T-cell lymphoma, and its inhibition induces growth arrest and apoptosis |
| Q34358718 | Selective inhibition of histone deacetylase 6 (HDAC6) induces DNA damage and sensitizes transformed cells to anticancer agents |
| Q38890886 | Selective inhibition of prostaglandin E2 receptors EP2 and EP4 modulates DNA methylation and histone modification machinery proteins in human endometriotic cells |
| Q37400663 | Synergistic activity of histone deacetylase and proteasome inhibition against pancreatic and hepatocellular cancer cell lines. |
| Q38005211 | Targeted gene therapies: tools, applications, optimization |
| Q36102767 | The Limonoids TS3 and Rubescin E Induce Apoptosis in Human Hepatoma Cell Lines and Interfere with NF-κB Signaling |
| Q53391458 | The effects of JNJ-26481585, a novel hydroxamate-based histone deacetylase inhibitor, on the development of multiple myeloma in the 5T2MM and 5T33MM murine models. |
| Q34725589 | The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F). |
| Q37295129 | The leukemic stem cell niche: current concepts and therapeutic opportunities |
| Q38016227 | Valproic acid for the treatment of malignant gliomas: review of the preclinical rationale and published clinical results |
| Q37824712 | Vorinostat in acute myeloid leukemia and myelodysplastic syndromes |
| Q39878284 | miR-449a targets HDAC-1 and induces growth arrest in prostate cancer |
Search more.